

# **C**ancer **I**mmunology **I**mmunotherapy

**Founding Editor**  
**G. Mathé**

Other Biological Response Modifications

**Volume 32 1990/91**

## **Editors in Chief**

**R. W. Baldwin E. Mihich**

## **Editorial Board**

**R. Arnon** Rehovot  
**S. Ben-Efraim** Tel Aviv  
**J. Bennett** Albany, NY  
**N. Bloksma** Utrecht  
**H. Blythman** Basel  
**V. S. Byers** Berkeley, CA  
**T. Carey** Ann Arbor, MI  
**M. Cheever** Seattle, WA  
**M. Colnaghi** Milan  
**S. Dray** Chicago, IL  
**S. Eccles** Sutton, Surrey  
**M. J. Ehrke** Buffalo, NY  
**E. Grimm** Houston, TX  
**K. Hellström** Seattle, WA

**K. Höffken** Essen  
**A. Houghton** New York, NY  
**J. Kieler** Copenhagen  
**H. Kirchner** Heidelberg  
**E. Kleinerman** Houston, TX  
**W. Knapp** Vienna  
**H. Kobayashi** Sapporo  
**M. Mastrangelo** Philadelphia, PA  
**J. McVie** London  
**M. Mitchell** Los Angeles, CA  
**M. Moore** London  
**R. J. North** Saranac Lake, NY  
**G. Parmiani** Milan  
**M. Price** Nottingham

**R. Rees** Sheffield  
**R. A. Reisfeld** La Jolla, CA  
**H.-J. Senn** St. Gallen  
**K. Sikora** London  
**Z. Steplewski** Philadelphia, PA  
**G. Stevenson** Southampton  
**J. Talmadge** King of Prussia, PA  
**E. Tsubura** Osaka  
**A. Uchida** Kyoto  
**F. Vánky** Stockholm  
**E. Vitetta** Dallas, TX  
**B. Vose** Cheshire



**Springer International**

## **Cancer Immunology Immunotherapy**

### **Other Biological Response Modifications**

This journal was founded in 1976. Founding editor: G. Mathé

Editors: R. W. Baldwin, E. Mihich

Published by Springer International

#### **Copyright**

*Submission of a manuscript implies:* that the work described has not been published before (except in the form of an abstract or as part of a published lecture, review, or thesis); that it is not under consideration for publication elsewhere; that its publication has been approved by all coauthors, if any, as well as by the responsible authorities at the institute where the work has been carried out; that, if and when the manuscript is accepted for publication, the authors agree to automatic transfer of the copyright to the publisher; and that the manuscript will not be published elsewhere in any language without the consent of the copyright holders.

All articles published in this journal are protected by copyright, which covers the exclusive rights to reproduce and distribute the article (e.g., as offprints), as well as all translation rights. No material published in this journal may be reproduced photographically or stored on microfilm, in electronic data bases, video disks, etc., without first obtaining written permission from the publisher.

The use of general descriptive names, trade names, trademarks, etc., in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.

While the advice and information in this journal is believed to be true and accurate at the date of its going to press, neither the authors, the editors, nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.

*Special regulations for photocopies in the USA:* Photocopies may be made for personal or inhouse use beyond the limitations stipulated under Section 107 or 108 of U.S. Copyright Law, provided a fee is paid. This fee is US \$ 0.20 per page, or a minimum of US \$ 1.00 if an article contains fewer than five pages. All fees should be paid to the Copyright Clearance Center, Inc., 21 Congress Street, Salem, MA 01970, USA, stating the ISSN 0340-7004, the volume, and the first and last page numbers of each article copied. The copyright owner's consent does not include copying for general distribution, promotion, new works, or resale. In these cases, specific written permission must first be obtained from the publisher.

Printed in Germany by E. Kieser GmbH Graphischer Betrieb, D-8902 Neusäß bei Augsburg

© Springer-Verlag Berlin Heidelberg 1991

# Contents of volume 32

No. 1 (pp 1-74) published 11 October 1990  
 No. 2 (pp 75-142) published 23 October 1990  
 No. 3 (pp 143-206) published 29 November 1990  
 No. 4 (pp 207-260) published 14 December 1990  
 No. 5 (pp 261-334) published 17 January 1991  
 No. 6 (pp 335-410) published 6 February 1991

Abe F, Matsuda A, Schneider M,  
 Talmadge JE: Effects of bestatin on  
 myelopoietic stem cells in normal and  
 cyclophosphamide-treated mice 75  
 Aebersold P → Morecki S  
 Ahn M-C → Bartik MM  
 Albertini MR, Nicklas JA, Chastenay BF,  
 Hunter TC, Albertini RJ, Clark SS,  
 Hank JA, Sondel PM: Analysis of T cell  
 receptor  $\beta$  and  $\gamma$  genes from peripheral  
 blood, regional lymph node and tumor-  
 infiltrating lymphocyte clones from  
 melanoma patients 325  
 Albertini RJ → Albertini MR  
 Aleva BJ → Steerenberg PA  
 Allavena P → Damia G  
 Anderer FA → Mueller EA  
 Anderson WF → Morecki S  
 Anichini A → Mazzocchi A  
 Avril M-F → Boue F  
 Baier J, Neumann HA, Ricken O: No  
 inhibition of interferon  $\gamma$  release in  
 human lymphocytes by Ciamezone 311  
 Baldwin RW → Pimm MV  
 Bankfalvi A → Kopper L  
 Barker E → Weiskirch LM  
 Barot-Ciorbaru R → Griesinger F  
 Barras C → Miescher S  
 Bartik MM, Ahn M-C, Baumgartel BA,  
 Hendricks RL, Mokyr MB: Presence of  
 an enlarged pool of MOPC-315-specific  
 cytotoxic T lymphocyte precursors in the  
 thymuses of mice that eradicated a large  
 MOPC-315 tumor as a consequence of  
 low-dose melphalan therapy 143  
 Baumgartel BA → Bartik MM  
 Baumgartel BA → Weiskirch LM  
 Bear HD → McKinnon JG  
 Belitsky P → Singh M  
 Bergmann L → Griesinger F  
 Besana C → Fortis C  
 Besselink CMLT → Steerenberg PA  
 Biffi M → Fortis C  
 Blaese RM → Morecki S  
 Blair AH → Singh M  
 Blottiere HM, Douillard J-Y, Koprowski  
 H, Steplewski Z: Humoral and cellular  
 responses of colorectal cancer patients  
 treated with monoclonal antibodies and  
 interferon  $\gamma$  29  
 Blumenthal RD, Kashi R, Stephens R,  
 Sharkey RM, Goldenberg DM:  
 Improved radioimmunotherapy of  
 colorectal cancer xenografts using  
 antibody mixtures against carcinoem-  
 bryonic antigen and colon-specific  
 antigen-p 303

Bogyo D, Fondy SRE, Finster L, Fondy C,  
 Patil S, Fondy TP: Cytochalasin-  
 B-induced immunosuppression of  
 murine allogeneic anti-tumor response  
 and the effect of recombinant human  
 interleukin-2 400  
 Bokkel Huinink WW ten → Hekman A  
 Boranić M → Gabrilovac J  
 Borri A → Fortis C  
 Boue F, Pastran Z, Spielmann M, Le Che-  
 valier T, Subirana R, Sevin D, Paoletti  
 C, Brandely M, Avril M-F, Sancho- Gar-  
 nier H, Tursz T: A phase I trial with  
 recombinant interferon  $\gamma$  (Roussel  
 UCLAF) in advanced cancer  
 patients 67  
 Brandely M → Boue F  
 Braun DP, Siziopikou KP, Casey LC,  
 Harris JE: The in vitro development of  
 cytotoxicity in response to granulocyte/  
 macrophage-colony-stimulating factor or  
 interferon  $\gamma$  in the peripheral blood  
 monocytes of patients with solid tumors:  
 Modulation by arachidonic acid meta-  
 bolic inhibitors 55  
 Bruner JM → Grimm EA  
 Bühring H-J → Pawelec G  
 Busch FW → Pawelec G  
 Capasso P → Miescher S  
 Carinhas J → Grimm EA  
 Casey LC → Braun DP  
 Castelli C → Mazzocchi A  
 Characiejus D, Dullens HFJ, Den Otter W:  
 Mechanisms of tumour rejection in the  
 murine DBA/2-SL2 concomitant  
 immunity system 179  
 Chastenay BF → Albertini MR  
 Clark DA → Hirte H  
 Clark SS → Albertini MR  
 Cohen BJ → Cohen MH  
 Cohen MH, Elin RJ, Cohen BJ: Hypo-  
 tension and disseminated intravascular  
 coagulation following intralesional  
 bacillus Calmette-Guérin therapy for  
 locally metastatic melanoma 315  
 Collins JL → Powell CB  
 Cooper S → Kohler M  
 Cornetta K → Morecki S  
 Cumber AJ → Wawrzynczak EJ  
 D'Aleo CJ → Rosenstrauss MJ  
 Damia G, Tagliabue G, Allavena P,  
 D'Incalci M: Flavone acetic acid antitu-  
 mour activity against a mouse pancreatic  
 adenocarcinoma is mediated by natural  
 killer cells 241  
 Datta S → Graham GM

Davis WL → Rosenstrauss MJ  
 De Jong WH → Steerenberg PA  
 Dénes L, Szende B, Hajós G, Szporny L,  
 Lapis K: Selective restoration of immu-  
 nosuppressive effect of cytotoxic agents  
 by thymopoietin fragments 51  
 Den Otter W → Steerenberg PA  
 Den Otter W → Characiejus D  
 Diener E → Ding L  
 D'Incalci M → Damia G  
 Ding L, Samuel J, MacLean GD, Noujaim  
 AA, Diener E, Longenecker BM: Effec-  
 tive drug-antibody targeting using a  
 novel monoclonal antibody against the  
 proliferative compartment of mamma-  
 lian squamous carcinomas 105  
 Dixon WT → Feyles V  
 Douillard J-Y → Blottiere HM  
 Drivsholm A → Nielsen HJ  
 Dullens HFJ → Characiejus D  
 Ehninger G → Pawelec G  
 Elin RJ → Cohen MH  
 Euhus DM, Gupta RK, Morton DL: Asso-  
 ciation between allo-immunoreactive  
 and xenoreactive subunits of a  
 glycoprotein tumor-associated  
 antigen 214  
 Favalli C → Garaci E  
 Ferrero E → Fortis C  
 Ferrone S → Graham GM  
 Feyles V, Dixon WT, Sikora LKJ,  
 McGarry RC, Jerry LM: Human mela-  
 noma-associated antigen expression on  
 human neuroblastoma cells: effects of  
 differentiation inducers 261  
 Figdor CG → Nijhuis EWP  
 Finster L → Bogyo D  
 Fisher PB → Graham GM  
 Flidner V von → Miescher S  
 Fondy C → Bogyo D  
 Fondy SRE → Bogyo D  
 Fondy TP → Bogyo D  
 Fortis C, Ferrero E, Besana C, Biffi M,  
 Heltai S, Galli L, Borri A, Schoenheit A,  
 Rugarli C: Recombinant interleukin-2  
 and lymphokine-activated killer cells in  
 renal cancer patients: I. phenotypic and  
 functional analysis of the peripheral  
 blood mononuclear cells 161  
 Gabrilovac J, Radacić M, Osmak M,  
 Boranić M: Opposing influence of age  
 on the growth and colony-forming  
 ability of mouse melanoma B16 and  
 mammary adenocarcinoma: correlation  
 with natural killer activity 45  
 Gallati H → Obrist R  
 Galli L → Fortis C  
 Garaci E, Mastino A, Pica F, Favalli C:  
 Combination treatment using thymosin  
 $\alpha$ 1 and interferon after cyclophospha-  
 mide is able to cure Lewis lung carci-  
 noma in mice 154  
 Geerse E → Steerenberg PA  
 Ghose T → Singh M  
 Giacomini P → Graham GM  
 Gilman SC → Rosenstrauss MJ  
 Glant TT → Kopper L  
 Goldenberg DM → Blumenthal RD

- Graham GM, Guarini L, Moulton TA, Datta S, Ferrone S, Giacomini P, Kerbel RS, Fisher PB: Potentiation of growth suppression and modulation of the antigenic phenotype in human melanoma cells by the combination of recombinant human fibroblast and immune interferons 382
- Griesbach A → Schirmacher V
- Griesinger F, Bergmann L, Barot-Ciorbaru R, Mitrou PS: Intrinsic B lymphocyte defect in untreated patients with Hodgkin's disease 256
- Grimm EA, Bruner JM, Carinhas J, Köppen JA, Loudon WG, Owen-Schaub L, Steck PA, Moser RP: Characterization of interleukin-2-initiated versus OKT3-initiated human tumor-infiltrating lymphocytes from glioblastoma multiforme: growth characteristics, cytolytic activity, and cell phenotype 391
- Guarini L → Graham GM
- Gunn B → Pimm MV
- Gupta RK → Euhus DM
- Hajós G → Dénes L
- Hank JA → Albertini MR
- Harris JE → Braun DP
- Hasegawa T → Konishi F
- Haynes A → Saleh MN
- Hekman A, Honselaar A, Vuist WMJ, Sein JJ, Rodenhuis S, Bokkel Huinink WW ten, Somers R, Rümke P, Melief CJM: Initial experience with treatment of human B cell lymphoma with anti-CD19 monoclonal antibody 364
- Heltai S → Fortis C
- Hendricks RL → Bartik MM
- Hengartner H → Kohler M
- Henry RV → Wawrzynczak EJ
- Herberman RB → Shimizu Y
- Hidaka S → Uno K
- Hirte H, Clark DA: Generation of lymphokine-activated killer cells in human ovarian carcinoma ascitic fluid: identification of transforming growth factor- $\beta$  as a suppressive factor 296
- Hoegen Pv → Schirmacher V
- Honselaar A → Hekman A
- Hoover SK → McKinnon JG
- Hunter TC → Albertini MR
- IJermans JNM → Scheringa M
- Imai S → Nio Y
- Inge TH → McKinnon JG
- Itoh T, Sakata Y, Yoshida Y, Tsushima K, Suzuki H, Saitoh S, Tamura Y, Ogawara H, Sugimoto N, Takemori H: Antitumor effect of combination of murine recombinant interferon  $\beta$ , murine recombinant interferon  $\gamma$ , and human recombinant interleukin-2 in MethA-bearing mice 88
- Iwatsuki S → Shimizu Y
- Jeekel J → Scheringa M
- Jerry LM → Feyles V
- Kan N → Satoh K
- Kao M-S → Powell CB
- Karson E → Morecki S
- Kashi R → Blumenthal RD
- Kasid A → Morecki S
- Kato T → Uno K
- Kawalec M → Skórski T
- Kawiak J → Skórski T
- Kerbel RS → Graham GM
- Khazaeli MB → Saleh MN
- Kirkwood JM, Robinson JE: Human IgG and IgM monoclonal antibodies against autologous melanoma produced by Epstein-Barr-virus-transformed B lymphocytes 228
- Klarlund K → Nielsen HJ
- Kodama M → Numa K
- Kohler M, Rüttner B, Cooper S, Hengartner H, Zinkernagel RM: Enhanced tumor susceptibility of immunocompetent mice infected with lymphocytic choriomeningitis virus 117
- Koizumi S → Nakarai T
- Konishi F, Tanaka K, Kumamoto S, Hasegawa T, Okuda M, Yano I, Yoshikai Y, Nomoto K: Enhanced resistance against *Escherichia coli* infection by subcutaneous administration of the hot-water extract of *Chlorella vulgaris* in cyclophosphamide-treated mice 1
- Konishi T → Uno K
- Köppen JA → Grimm EA
- Kopper L, Bankfalvi A, Mihalik R, Glant TT, Timar J: Proteoglycan-targeted antibodies as markers on non-Hodgkin lymphoma xenografts 137
- Koprowski H → Blottiere HM
- Kralovec J → Singh M
- Kumamoto S → Konishi F
- Lapis K → Dénes L
- Le Chevalier T → Boue F
- Lee JY → Saleh MN
- Lehner B, Schlag P, Liebrich W, Schirmacher V: Postoperative active specific immunization in curatively resected colorectal cancer patients with a virus-modified autologous tumor cell vaccine 173
- Liebrich W → Lehner B
- Lier RAW v → Nijhuis EWP
- LoBuglio AF → Saleh MN
- Longenecker BM → Ding L
- Lopes AD → Rosenstrauss MJ
- Lord JM → Pimm MV
- Loudon WG → Grimm EA
- Machen LL → Winkelstein A
- MacLean GD → Ding L
- Mansa B → Nielsen HJ
- Marquet RL → Scheringa M
- Marquis DM → McCune CS
- Massad LS → Powell CB
- Mastino A → Garaci E
- Matsuda A → Abe F
- Mazzocchi A, Anichini A, Castelli C, Sensi M, Poli F, Russo C, Parmiani G: T lymphocytes can mediate lysis of autologous melanoma cells by multiple mechanisms: evidence with a single T cell clone 13
- McCune CS, O'Donnell RW, Marquis DM, Sahasrabudhe DM: Renal cell carcinoma treated by vaccines for active specific immunotherapy: correlation of survival with skin testing by autologous tumor cells 62
- McGarry RC → Feyles V
- McKinnon JG, Hoover SK, Inge TH, Bear HD: Activation and expansion of cytotoxic T lymphocytes from tumor-draining lymph nodes 38
- Melief CJM → Hekman A
- Miescher S, Schreyer M, Barras C, Capasso P, Fliedner V von: Sparse distribution of  $\gamma/\delta$  T lymphocytes around human epithelial tumors predominantly infiltrated by primed/memory T cells 81
- Mihalik R → Kopper L
- Minato N → Morita T
- Mise K → Satoh K
- Mitrou PS → Griesinger F
- Moesgaard F → Nielsen HJ
- Mokyr MB → Bartik MM
- Mokyr MB → Weiskirch LM
- Morecki S, Karson E, Cornetta K, Kasid A, Aebersold P, Blaese RM, Anderson WF, Rosenberg SA: Retrovirus-mediated gene transfer into CD4<sup>+</sup> and CD8<sup>+</sup> human T cell subsets derived from tumor-infiltrating lymphocytes and peripheral blood mononuclear cell 342
- Morimoto H → Nio Y
- Morita T, Tokue A, Minato N: Analysis of natural killer activity and natural killer cell subsets in patients with bladder cancer 191
- Morton DL → Euhus DM
- Moser RP → Grimm EA
- Moulton TA → Graham GM
- Mueller EA, Anderer FA: A *Viscum album* oligosaccharide activating human natural cytotoxicity is an interferon  $\gamma$  inducer 221
- Müller C → Pawelec G
- Müller R → Obrist R
- Muramatsu S → Uno K
- Mutch DG → Powell CB
- Nakamura S → Uno K
- Nakanishi M → Satoh K
- Nakarai T, Ueno Y, Ueno Y, Koizumi S: Paradoxical enhancement of interleukin-2-mediated cytotoxicity against K562 cells by addition of a low dose of methotrexate 8
- Neumann HA → Baier J
- Nicklas JA → Albertini MR
- Nielsen H → Nielsen HJ
- Nielsen HJ, Nielsen H, Moesgaard F, Tvede N, Klarlund K, Mansa B, Drivsholm A: The effect of ranitidine on cellular immunity in patients with multiple myeloma 201
- Nijhuis EWP, Wiel-van Kemenade E v/d, Figdor CG, Lier RAW v: Activation and expansion of tumour-infiltrating lymphocytes by anti-CD3 and anti-CD28 monoclonal antibodies 245
- Nio Y, Shiraishi T, Tsubono M, Morimoto H, Tseng C-C, Imai S, Tobe T: In vitro immunomodulating effect of protein-bound polysaccharide, PSK on peripheral blood, regional nodes, and spleen lymphocytes in patients with gastric cancer 335
- Nomoto K → Konishi F
- Noujaim AA → Ding L
- Numa K, Tani T, Kodama M: Trial of anticancer immunotherapy with immobilized pokeweed mitogen: immunotherapy by extracorporeal circulation 125

- Obrecht JP → Obrist R  
 Obrist R, Schmidli J, Müller R, Gallati H, Obrecht JP: Acute and subacute toxicity of chemotactic conjugates between monoclonal antibody and fMet-Leu-Phe in humans: a phase I clinical trial 406  
 O'Donnell RW → McCune CS  
 Ogasawara H → Itoh T  
 Ohgaki K → Satoh K  
 Oke V → Sacks PG  
 Okino T → Satoh K  
 Okuda M → Konishi F  
 Osmak M → Gabrilovac J  
 Owen-Schaub L → Grimm EA  
 Paoletti C → Boue F  
 Parmiani G → Mazzocchi A  
 Parnell GD → Wawrzynczak EJ  
 Pastran Z → Boue F  
 Patil S → Bogoy D  
 Pawelec G, Ehninger G, Schmidt H, Müller C, Bühring H-J, Reutter M, Busch FW: Susceptibility of autologous target cells to lysis by lymphokine-activated effectors from interferon- $\alpha$ -treated chronic myelogenous leukaemia patients 167  
 Pica F → Garaci E  
 Pimm MV, Gunn B, Lord JM, Baldwin RW: The influence of anti-(ricin toxin A chain) monoclonal antibodies on the pharmacokinetics of ricin toxin A chain and recombinant ricin A chain in mice 235  
 Poels LG → Steerenberg PA  
 Poli F → Mazzocchi A  
 Powell CB, Mutch DG, Massad LS, Kao M-S, Collins JL: Common expression of a tumor necrosis factor resistance mechanism among gynecological malignancies 131  
 Racz T → Sacks PG  
 Radacić M → Gabrilovac J  
 Reutter M → Pawelec G  
 Ricken O → Baier J  
 Rieber EP → Wawrzynczak EJ  
 Robinson JE → Kirkwood JM  
 Rodenhuis S → Hekman A  
 Rogers KJ → Saleh MN  
 Rosenberg SA → Morecki S  
 Rosenstrauss MJ, Davis WL, Lopes AD, D'Aleo CJ, Gilman SC: Carbohydrate-derivatized immunoconjugate of the anti-(carcinoembryonic antigen) monoclonal antibody C46: immunohistological reactivity and pharmacokinetic comparison with a randomly derivatized C46 immunoconjugate 207  
 Rugarli C → Fortis C  
 Ruitenber EJ → Steerenberg PA  
 Rümke P → Hekman A  
 Russo C → Mazzocchi A  
 Rutten VPMG → Steerenberg PA  
 Rüttner B → Kohler M  
 Sacks PG, Taylor DL, Racz T, Vasey T, Oke V, Schantz SP: A multicellular tumor spheroid model of cellular immunity against head and neck cancer 195  
 Sahasrabudhe DM → McCune CS  
 Saitoh S → Itoh T  
 Sakata Y → Itoh T  
 Saleh MN, LoBuglio AF, Wheeler RH, Rogers KJ, Haynes A, Lee JY, Khazaeli MB: A phase II trial of murine monoclonal antibody 17-1A and interferon- $\gamma$ : clinical and immunological data 185  
 Salva N → Winkelstein A  
 Samuel J → Ding L  
 Sancho-Garnier H → Boue F  
 Satoh K, Kan N, Okino T, Nakanishi M, Mise K, Teramura Y, Yamasaki S, Ohgaki K, Tobe T: A murine plasmacytoma MOPC 104E resistant to cyclophosphamide is resistant to immunotherapy 273  
 Schantz SP → Sacks PG  
 Scheper RJ → Steerenberg PA  
 Scheringa M, IJermans JNM, Jeekel J, Marquet RL: The antitumor activity of the interferon inducer bropirimine is partially mediated by endogenous tumor necrosis factor  $\alpha$  251  
 Schild H-J → Schirmmacher V  
 Schirmmacher V → Lehner B  
 Schirmmacher V, Hoegen Pv, Griesbach A, Schild H-J, Zangemeister-Wittke U: Specific eradication of micrometastases by transfer of tumor-immune T cells from major-histocompatibility-complex congenic mice 373  
 Schlag P → Lehner B  
 Schmidli J → Obrist R  
 Schmidt H → Pawelec G  
 Schneider M → Abe F  
 Schoenheit A → Fortis C  
 Schreyer M → Miescher S  
 Sein JJ → Hekman A  
 Sensi M → Mazzocchi A  
 Sevin D → Boue F  
 Sharkey RM → Blumenthal RD  
 Shimizu Y, Iwatsuki S, Herberman RB, Whiteside TL: Effects of cytokines on in vitro growth of tumor-infiltrating lymphocytes obtained from human primary and metastatic liver tumors 280  
 Shiraishi T → Nio Y  
 Sikora LKJ → Feyles V  
 Singh M, Ghose T, Kralovec J, Blair AH, Belitsky P: Inhibition of human renal cancer by monoclonal-anti-body-linked methotrexate in an ascites tumor model 331  
 Siziopikou KP → Braun DP  
 Skórski T, Kawalec M, Kawiak J: Successful adoptive immunotherapy of minimal residual disease after chemoradiotherapy and transplantation of bone marrow purged of leukaemia with mafosfamide 71  
 Somers R → Hekman A  
 Sondel PM → Albertini MR  
 Spielmann M → Boue F  
 Steck PA → Grimm EA  
 Steerenberg PA, De Jong WH, Geerse E, Aleva BJ, Besselink CMLT, Van Rens BTM, Rutten VPMG, Poels LG, Scheper RJ, Den Otter W, Ruitenber EJ: Major histocompatibility complex class II antigen expression during potentiation of line-10 tumor immunity after intralesional administration of bacillus Calmette-Guérin 95  
 Stephens R → Blumenthal RD  
 Steplewski Z → Blottiere HM  
 Subirana R → Boue F  
 Sugimoto N → Itoh T  
 Suzuki H → Itoh T  
 Szende B → Dénes L  
 Szporny L → Dénes L  
 Tagliabue G → Damia G  
 Takema M → Uno K  
 Takemori H → Itoh T  
 Talmadge JE → Abe F  
 Tamura Y → Itoh T  
 Tanaka K → Konishi F  
 Tanaka R → Uno K  
 Tani T → Numa K  
 Taylor DL → Sacks PG  
 Teramura Y → Satoh K  
 Thorpe PE → Wawrzynczak EJ  
 Timar J → Kopper L  
 Tobe T → Satoh K  
 Tobe T → Nio Y  
 Tokue A → Morita T  
 Tseng C-C → Nio Y  
 Tsubono M → Nio Y  
 Tsushima K → Itoh T  
 Tursz T → Boue F  
 Tvede N → Nielsen HJ  
 Ueno Y → Nakarai T  
 Uno K, Takema M, Hidaka S, Tanaka R, Konishi T, Kato T, Nakamura S, Muramatsu S: Induction of antitumor activity in macrophages by mycoplasmas in concert with interferon 22  
 Van Rens BTM → Steerenberg PA  
 Vasey T → Sacks PG  
 Vuist WMJ → Hekman A  
 Watson GJ → Wawrzynczak EJ  
 Wawrzynczak EJ, Watson GJ, Cumber AJ, Henry RV, Parnell GD, Rieber EP, Thorpe PE: Blocked and non-blocked ricin immunotoxins against the CD4<sup>+</sup> antigen exhibit higher cytotoxic potency than a ricin A chain immunotoxin potentiated with ricin B chain or with a ricin B chain immunotoxin 289  
 Weaver LD → Winkelstein A  
 Weiskirch LM, Baumgartel BA, Barker E, Mokyr MB: Phorbol ester-induced enhancement in lytic activity of CD8<sup>+</sup> splenic T cells from low-dose melphalan-treated MOPC-315-tumor bearers 353  
 Wheeler RH → Saleh MN  
 Whiteside TL → Shimizu Y  
 Wiel-van Kemenade E v/d → Nijhuis EWP  
 Winkelstein A, Weaver LD, Salva N, Machen LL: Interleukin-2-induced lymphoproliferative responses 110  
 Yamasaki S → Satoh K  
 Yano I → Konishi F  
 Yoshida Y → Itoh T  
 Yoshikai Y → Konishi F  
 Zangemeister-Wittke U → Schirmmacher V  
 Zinkernagel RM → Kohler M  
 Indexed in *Current Contents*